Sugammadex - Merck

While the rest of Merck's pipeline has been refocused and driven forward, sugammadex remains mired in regulatory woes at the FDA.

What's wrong with sugammadex? Plenty, evidently. Earlier this year the FDA capped 7 years of discussions and setbacks with its third straight rejection.

Regulators have never been satisfied with the hypersensitivity study that was done for the application, requiring more site inspections. And that forced the FDA to cancel another advisory committee review and spurn the latest application.

Merck ($MRK) has consistently maintained that this program is one of their crown jewels in the pipeline, even gaining R&D chief Roger Perlmutter's endorsement after he joined the pharma giant. But the drug has instead tended to highlight the old Merck's unending R&D woes prior to Perlmutter's arrival.

For more:
FDA bats down Merck's sugammadex in third rejection
Merck can't get the sugammadex curse lifted, faces 3rd FDA rejection
Merck R&D hammered by another setback as FDA rejects anesthesia drug (again)

Sugammadex - Merck

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.